Liquidia Target of Unusually High Options Trading (NASDAQ:LQDA)

Liquidia Corporation (NASDAQ:LQDA) saw unusually large options trading on Friday. Stock traders bought 54,585 call options on the stock. This represents an increase of 375% compared to the average volume of 11,501 call options.

Liquidia Stock Up 0.7%

NASDAQ LQDA traded up $0.26 during trading on Friday, hitting $39.05. The company’s stock had a trading volume of 1,826,787 shares, compared to its average volume of 2,648,807. Liquidia has a fifty-two week low of $11.26 and a fifty-two week high of $41.57. The company has a market cap of $3.40 billion, a PE ratio of -27.07, a P/E/G ratio of 0.68 and a beta of 0.48. The company has a debt-to-equity ratio of 6.19, a current ratio of 2.20 and a quick ratio of 1.96. The business’s 50 day simple moving average is $32.68 and its 200-day simple moving average is $25.77.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings results on Monday, November 3rd. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.41. The business had revenue of $54.34 million for the quarter, compared to analyst estimates of $18.86 million. Liquidia had a negative net margin of 176.04% and a negative return on equity of 296.78%. The company’s revenue was up 1106.7% compared to the same quarter last year. On average, equities analysts anticipate that Liquidia will post -1.51 EPS for the current fiscal year.

Insider Buying and Selling at Liquidia

In other Liquidia news, General Counsel Russell Schundler sold 27,289 shares of the company’s stock in a transaction on Monday, January 12th. The stock was sold at an average price of $37.43, for a total value of $1,021,427.27. Following the completion of the sale, the general counsel directly owned 579,394 shares in the company, valued at approximately $21,686,717.42. This represents a 4.50% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Jason Adair sold 13,548 shares of the stock in a transaction on Monday, January 12th. The stock was sold at an average price of $37.43, for a total value of $507,101.64. Following the transaction, the insider directly owned 184,174 shares in the company, valued at $6,893,632.82. The trade was a 6.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 323,354 shares of company stock worth $11,046,731 over the last quarter. Insiders own 26.50% of the company’s stock.

Institutional Trading of Liquidia

Large investors have recently added to or reduced their stakes in the company. XTX Topco Ltd purchased a new position in shares of Liquidia in the second quarter worth about $1,485,000. Tyro Capital Management LLC purchased a new stake in Liquidia in the second quarter valued at approximately $15,473,000. Diametric Capital LP raised its position in Liquidia by 72.5% during the 2nd quarter. Diametric Capital LP now owns 148,601 shares of the company’s stock worth $1,852,000 after buying an additional 62,443 shares during the last quarter. Y Intercept Hong Kong Ltd acquired a new stake in Liquidia during the 2nd quarter valued at approximately $775,000. Finally, Pale Fire Capital SE purchased a new stake in Liquidia in the 2nd quarter worth approximately $1,068,000. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Liquidia News Summary

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Zacks Research upgraded LQDA to a “strong-buy” and published a momentum-focused note highlighting recent revenue beats and upward price momentum — a catalyst for buys from momentum and growth-oriented investors. Zacks: Liquidia is a great momentum stock
• Neutral Sentiment: Laughing Water Capital mentioned Liquidia in its Q4 2025 investor letter — useful color on institutional interest/ownership but not a direct operational update. Institutional mentions can support sentiment over time. Laughing Water Capital update
• Neutral Sentiment: Liquidia presented at the J.P. Morgan Healthcare Conference (transcript released). Conference presentations can provide pipeline and commercial updates; investors will watch for any new guidance or milestone timing. J.P. Morgan Healthcare Conference transcript
• Negative Sentiment: Multiple insider sell filings surfaced this morning — filings show several officers/directors (including a CAO filing and a reported sale by Roger Jeffs) with aggregate reported proceeds of roughly $3.0M across the disclosed transactions. Insider selling can pressure sentiment if investors interpret it as reduced insider conviction, though context (planned sales, diversification, option exercises) matters. Roger Jeffs sells 66,610 shares CAO sells shares

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. Jefferies Financial Group lifted their price objective on shares of Liquidia from $45.00 to $55.00 and gave the company a “buy” rating in a report on Tuesday. HC Wainwright boosted their price target on Liquidia from $35.00 to $50.00 and gave the stock a “buy” rating in a research report on Tuesday, November 4th. Raymond James Financial reaffirmed a “strong-buy” rating and set a $47.00 price objective on shares of Liquidia in a research report on Tuesday, November 4th. Needham & Company LLC boosted their target price on shares of Liquidia from $36.00 to $52.00 and gave the stock a “buy” rating in a report on Tuesday, November 4th. Finally, Zacks Research upgraded shares of Liquidia from a “hold” rating to a “strong-buy” rating in a report on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $39.67.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).